FOLH1 and prostate cancer: ,9 Data from the phase 3, prospective, multicenter, open-label, single-arm SPOTLIGHT study show high affinity, prostate-specific membrane antigen–targeting 18F-flotufolastat to be well tolerated and to offer a clinically meaningful verified detection rate (VDR) for the localization of recurrent prostate cancer.8